Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Lung Cancer

Free Subscription Articles published in PLoS One Retrieve available abstracts of 284 articles: HTML format

Single Articles

January 2022
1. VANNINI I, Ferracin M, Fabbri F, Fabbri M, et al
   Overexpression of ultraconserved region 83- induces lung cancer tumorigenesis.
   PLoS One. 2022;17:e0261464.
   PubMed     Abstract available
   
   
   
2. MENG G, Liu X, Ma T, Lv D, et al
   Predictive value of tumor mutational burden for immunotherapy in non-small cell lung cancer: A systematic review and meta-analysis.
   PLoS One. 2022;17:e0263629.
   PubMed     Abstract available
   
   
   
3. PATEL YS, Hanna WC, Fahim C, Shargall Y, et al
   RAVAL trial: Protocol of an international, multi-centered, blinded, randomized controlled trial comparing robotic-assisted versus video-assisted lobectomy for early-stage lung cancer.
   PLoS One. 2022;17:e0261767.
   PubMed     Abstract available
   
   
   
4. NINOMIYA K, Arimura H, Yoshitake T, Hirose TA, et al
   Synergistic combination of a topologically invariant imaging signature and a biomarker for the accurate prediction of symptomatic radiation pneumonitis before stereotactic ablative radiotherapy for lung cancer: A retrospective analysis.
   PLoS One. 2022;17:e0263292.
   PubMed     Abstract available
   
   
   
5. OTTE R, Roodbeen R, Boland G, Noordman J, et al
   Affective communication with patients with limited health literacy in the palliative phase of COPD or lung cancer: Analysis of video-recorded consultations in outpatient care.
   PLoS One. 2022;17:e0263433.
   PubMed     Abstract available
   
   
   
6. TAKADA K, Shimokawa M, Takamori S, Shimamatsu S, et al
   The clinical impact of concomitant medication use on the outcome of postoperative recurrent non-small-cell lung cancer in patients receiving immune checkpoint inhibitors.
   PLoS One. 2022;17:e0263247.
   PubMed     Abstract available
   
   
   
7. WILLIAMSON DFK, Marris SRN, Rojas-Rudilla V, Bruce JL, et al
   Detection of EGFR mutations in non-small cell lung cancer by droplet digital PCR.
   PLoS One. 2022;17:e0264201.
   PubMed     Abstract available
   
   
   
8. ALHAKAMY NA, Okbazghi SZ, A Alfaleh M, H Abdulaal W, et al
   Wasp venom peptide improves the proapoptotic activity of alendronate sodium in A549 lung cancer cells.
   PLoS One. 2022;17:e0264093.
   PubMed     Abstract available
   
   
   
9. KARADZOVSKA-KOTEVSKA M, Brunnstrom H, Kosieradzki J, Ek L, et al
   Feasibility of EBUS-TBNA for histopathological and molecular diagnostics of NSCLC-A retrospective single-center experience.
   PLoS One. 2022;17:e0263342.
   PubMed     Abstract available
   
   
   
10. LI F, Ye P, Cai P, Dong D, et al
    Prevalence of targeted therapy-related genetic variations in NSCLC and their relationship with clinicopathological characteristics.
    PLoS One. 2022;17:e0262822.
    PubMed     Abstract available
    
    
    
11. WATANABE Y, Nakagawa T, Fukai K, Honda T, et al
    Descriptive study of chest x-ray examination in mandatory annual health examinations at the workplace in Japan.
    PLoS One. 2022;17:e0262404.
    PubMed     Abstract available
    
    
    
12. KAEWJANTHONG P, Sooksai S, Sasano H, Hutvagner G, et al
    Cell-penetrating peptides containing the progesterone receptor polyproline domain inhibits EGF signaling and cell proliferation in lung cancer cells.
    PLoS One. 2022;17:e0264717.
    PubMed     Abstract available
    
    
    
13. LIANG H, Peng J
    LncRNA HOTAIR promotes proliferation, invasion and migration in NSCLC cells via the CCL22 signaling pathway.
    PLoS One. 2022;17:e0263997.
    PubMed     Abstract available
    
    
    
14. MIURA K
    Stiffness reduction and collagenase resistance of aging lungs measured using scanning acoustic microscopy.
    PLoS One. 2022;17:e0263926.
    PubMed     Abstract available
    
    
    
15. WEBER JD, Spiro JE, Scheffler M, Wolf J, et al
    Reproducibility of dynamic contrast enhanced MRI derived transfer coefficient Ktrans in lung cancer.
    PLoS One. 2022;17:e0265056.
    PubMed     Abstract available
    
    
    
16. YE W, Huang T
    Correlation analysis of m6A-modified regulators with immune microenvironment infiltrating cells in lung adenocarcinoma.
    PLoS One. 2022;17:e0264384.
    PubMed     Abstract available
    
    
    
17. LIMA KYN, Cancela MC, de Souza DLB
    Spatial assessment of advanced-stage diagnosis and lung cancer mortality in Brazil.
    PLoS One. 2022;17:e0265321.
    PubMed     Abstract available
    
    
    
18. LIU H, Li T, Dong C, Lyu J, et al
    Identification of miRNA signature for predicting the prognostic biomarker of squamous cell lung carcinoma.
    PLoS One. 2022;17:e0264645.
    PubMed     Abstract available
    
    
    
19. OSE N, Takeuchi Y, Sakamaki Y, Kadota Y, et al
    Detection of lymph node metastasis in non-small cell lung cancer using the new system of one-step nucleic acid amplification assay.
    PLoS One. 2022;17:e0265603.
    PubMed     Abstract available
    
    
    
20. JEGANATHAN V, Knight S, Bricknell M, Ridgers A, et al
    Impact of smoking status and chronic obstructive pulmonary disease on pulmonary complications post lung cancer surgery.
    PLoS One. 2022;17:e0266052.
    PubMed     Abstract available
    
    
    
21. DALAH EZ, Obaideen A, Anam S, Alzimami K, et al
    Gender based lung cancer risks for symptomatic coronary artery disease patients undergone cardiac CT.
    PLoS One. 2022;17:e0265609.
    PubMed     Abstract available
    
    
    
22. FREDRIKSEN V, Sevle SOM, Pedersen A, Lango T, et al
    Teacher-student approach for lung tumor segmentation from mixed-supervised datasets.
    PLoS One. 2022;17:e0266147.
    PubMed     Abstract available
    
    
    
23. GAROFALO M, Jeon YJ, Nuovo GJ, Middleton J, et al
    Correction: MiR-34a/c-Dependent PDGFR-alpha/beta Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer.
    PLoS One. 2022;17:e0267628.
    PubMed     Abstract available
    
    
    
24. SQUARA PA, Luu VP, Perol D, Coudert B, et al
    Personalized Reimbursement Model (PRM) program: A real-world data platform of cancer drugs use to improve and personalize drug pricing and reimbursement in France.
    PLoS One. 2022;17:e0267242.
    PubMed     Abstract available
    
    
    
25. HO HL, Jiang Y, Chiang CL, Karwowska S, et al
    Efficacy of liquid biopsy for disease monitoring and early prediction of tumor progression in EGFR mutation-positive non-small cell lung cancer.
    PLoS One. 2022;17:e0267362.
    PubMed     Abstract available
    
    
    
26. MIAO J, Wei H, Cui J, Zhang Q, et al
    The prognosis of different distant metastases pattern in malignant tumors of the adrenal glands: A population-based retrospective study.
    PLoS One. 2022;17:e0264431.
    PubMed     Abstract available
    
    
    
27. SUNG HW, Choi SE, Chu CH, Ouyang M, et al
    Sensitizing drug-resistant cancer cells from blood using microfluidic electroporator.
    PLoS One. 2022;17:e0264907.
    PubMed     Abstract available
    
    
    
28. LOPEZ-JIMENEZ T, Duarte-Salles T, Plana-Ripoll O, Recalde M, et al
    Association between metabolic syndrome and 13 types of cancer in Catalonia: A matched case-control study.
    PLoS One. 2022;17:e0264634.
    PubMed     Abstract available
    
    
    
29. CIERESZKO A, Dietrich MA, Slowinska M, Nynca J, et al
    Application of two-dimensional difference gel electrophoresis to identify protein changes between center, margin, and adjacent non-tumor tissues obtained from non-small-cell lung cancer with adenocarcinoma or squamous cell carcinoma subtype.
    PLoS One. 2022;17:e0268073.
    PubMed     Abstract available
    
    
    
30. CHO KS, Kim S, Chun HB, Cheon JH, et al
    Efficient gene transfection to lung cancer cells via Folate-PEI-Sorbitol gene transporter.
    PLoS One. 2022;17:e0266181.
    PubMed     Abstract available
    
    
    
31. LEISER D, Samanta S, Strauss J, Eley J, et al
    Correction: Role of caveolin-1 as a biomarker for radiation resistance and tumor aggression in lung cancer.
    PLoS One. 2022;17:e0268256.
    PubMed     Abstract available
    
    
    
32. POH J, Ngeow KC, Pek M, Tan KH, et al
    Analytical and clinical validation of an amplicon-based next generation sequencing assay for ultrasensitive detection of circulating tumor DNA.
    PLoS One. 2022;17:e0267389.
    PubMed     Abstract available
    
    
    
33. BIZZO BC, Ebrahimian S, Walters ME, Michalski MH, et al
    Validation pipeline for machine learning algorithm assessment for multiple vendors.
    PLoS One. 2022;17:e0267213.
    PubMed     Abstract available
    
    
    
34. LI S, Counter CM
    Non-canonical genomic driver mutations of urethane carcinogenesis.
    PLoS One. 2022;17:e0267147.
    PubMed     Abstract available
    
    
    
35. CHEN Z, Xiong H, Shen H, You Q, et al
    Autophagy characteristics and establishment of autophagy prognostic models in lung adenocarcinoma and lung squamous cell carcinoma.
    PLoS One. 2022;17:e0266070.
    PubMed     Abstract available
    
    
    
36. PAEZ R, Shah C, Cords AJ, Muterspaugh A, et al
    18F-FSPG PET imaging for the evaluation of indeterminate pulmonary nodules.
    PLoS One. 2022;17:e0265427.
    PubMed     Abstract available
    
    
    
37. OSAWA T, Abe T, Kikuchi H, Matsumoto R, et al
    Validation of an online application to identify potential immune-related adverse events associated with immune checkpoint inhibitors based on the patient's symptoms.
    PLoS One. 2022;17:e0265230.
    PubMed     Abstract available
    
    
    
38. WANG H, Li C, Yang R, Jin J, et al
    Prognostic value of the platelet-to-lymphocyte ratio in lung cancer patients receiving immunotherapy: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0268288.
    PubMed     Abstract available
    
    
    
39. KRAWCZYK P, Grzycka-Kowalczyk L, Blach J, Reszka K, et al
    The efficacy of T790M mutation testing in liquid biopsy-Real clinic data.
    PLoS One. 2022;17:e0267846.
    PubMed     Abstract available
    
    
    
40. MURCHISON JT, Ritchie G, Senyszak D, Nijwening JH, et al
    Validation of a deep learning computer aided system for CT based lung nodule detection, classification, and growth rate estimation in a routine clinical population.
    PLoS One. 2022;17:e0266799.
    PubMed     Abstract available
    
    
    
41. KIM Y, Zhu L, Zhu H, Li X, et al
    Characterizing cancer and COVID-19 outcomes using electronic health records.
    PLoS One. 2022;17:e0267584.
    PubMed     Abstract available
    
    
    
42. PATEL P, Raval M, Manvar A, Airao V, et al
    Lung cancer targeting efficiency of Silibinin loaded Poly Caprolactone /Pluronic F68 Inhalable nanoparticles: In vitro and In vivo study.
    PLoS One. 2022;17:e0267257.
    PubMed     Abstract available
    
    
    
43. LUGTU EJ, Ramos DB, Agpalza AJ, Cabral EA, et al
    Artificial neural network in the discrimination of lung cancer based on infrared spectroscopy.
    PLoS One. 2022;17:e0268329.
    PubMed     Abstract available
    
    
    
44. KOSKINEN A, Hemminki O, Forsti A, Hemminki K, et al
    Incidence and survival in laryngeal and lung cancers in Finland and Sweden through a half century.
    PLoS One. 2022;17:e0268922.
    PubMed     Abstract available
    
    
    
45. KISHI N, Matsuo Y, Hanazawa H, Iizuka Y, et al
    Lack of an association between marital status and survival in patients receiving stereotactic body radiotherapy for early-stage non-small-cell lung cancer.
    PLoS One. 2022;17:e0269463.
    PubMed     Abstract available
    
    
    
46. SPINI A, Rosellini P, Bellan C, Furiesi F, et al
    Development and validation of a case-finding algorithm for the identification of non-small cell lung cancers in a region-wide Italian pathology registry.
    PLoS One. 2022;17:e0269232.
    PubMed     Abstract available
    
    
    
47. TANG Y, Luo J, Yang Y, Liu S, et al
    Overexpression of p-4EBP1 associates with p-eIF4E and predicts poor prognosis for non-small cell lung cancer patients with resection.
    PLoS One. 2022;17:e0265465.
    PubMed     Abstract available
    
    
    
48. PAGE R, Patil D, Akolkar D, Murthy SS, et al
    Circulating tumor cell assay to non-invasively evaluate PD-L1 and other therapeutic targets in multiple cancers.
    PLoS One. 2022;17:e0270139.
    PubMed     Abstract available
    
    
    
49. LI P, Wang Q, Liu L, Zhou R, et al
    Efficacy and safety of oral Chinese medicine on cancer-related fatigue for lung cancer patients after chemotherapy: Protocol for systematic review and meta-analysis.
    PLoS One. 2022;17:e0270203.
    PubMed     Abstract available
    
    
    
50. JIANG X, Chen J, Zheng M, Jia H, et al
    Cost-effectiveness analysis of durvalumab as a maintenance treatment for patients with locally advanced, unresectable, stage nsclc in china.
    PLoS One. 2022;17:e0270118.
    PubMed     Abstract available
    
    
    
51. XIONG Z, Jiang Y, Tian D, Zhang J, et al
    Radiomics for identifying lung adenocarcinomas with predominant lepidic growth manifesting as large pure ground-glass nodules on CT images.
    PLoS One. 2022;17:e0269356.
    PubMed     Abstract available
    
    
    
52. KIM C, Kwack T, Kim W, Cha J, et al
    Accuracy of two deep learning-based reconstruction methods compared with an adaptive statistical iterative reconstruction method for solid and ground-glass nodule volumetry on low-dose and ultra-low-dose chest computed tomography: A phantom study.
    PLoS One. 2022;17:e0270122.
    PubMed     Abstract available
    
    
    
53. CASTAGNOLI F, Doran S, Lunn J, Minchom A, et al
    Splenic volume as a predictor of treatment response in patients with non-small cell lung cancer receiving immunotherapy.
    PLoS One. 2022;17:e0270950.
    PubMed     Abstract available
    
    
    
54. MAZZONE P, Dotson T, Wahidi MM, Bernstein M, et al
    Clinical validation and utility of Percepta GSC for the evaluation of lung cancer.
    PLoS One. 2022;17:e0268567.
    PubMed     Abstract available
    
    
    January 2021
55. FINNEGAN RN, Orlandini L, Liao X, Yin J, et al
    Feasibility of using a novel automatic cardiac segmentation algorithm in the clinical routine of lung cancer patients.
    PLoS One. 2021;16:e0245364.
    PubMed     Abstract available
    
    
    
56. EL-TURK N, Chou MSH, Ting NCH, Girgis A, et al
    Treatment burden experienced by patients with lung cancer.
    PLoS One. 2021;16:e0245492.
    PubMed     Abstract available
    
    
    
57. LAYTRAGOON LEWIN N, Karlsson JE, Robinsson D, Fagerberg M, et al
    Influence of single nucleotide polymorphisms among cigarette smoking and non-smoking patients with coronary artery disease, urinary bladder cancer and lung cancer.
    PLoS One. 2021;16:e0243084.
    PubMed     Abstract available
    
    
    
58. FUNG AS, Kopciuk K, Dean ML, D'Silva A, et al
    CXCR4 expression in lung carcinogenesis: Evaluating gender-specific differences in survival outcomes based on CXCR4 expression in early stage non-small cell lung cancer patients.
    PLoS One. 2021;16:e0241240.
    PubMed     Abstract available
    
    
    
59. PATIL NS, Zou W, Mocci S, Sandler A, et al
    C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients.
    PLoS One. 2021;16:e0246486.
    PubMed     Abstract available
    
    
    
60. MAPANGA W, Norris SA, Chen WC, Blanchard C, et al
    Consensus study on the health system and patient-related barriers for lung cancer management in South Africa.
    PLoS One. 2021;16:e0246716.
    PubMed     Abstract available
    
    
    
61. LEI Z, Yang W, Zuo Y
    Beta-blocker and survival in patients with lung cancer: A meta-analysis.
    PLoS One. 2021;16:e0245773.
    PubMed     Abstract available
    
    
    
62. YOU JHS, Cho WCS, Ming WK, Li YC, et al
    EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong - A cost-effectiveness analysis.
    PLoS One. 2021;16:e0247860.
    PubMed     Abstract available
    
    
    
63. YU G, Cai Q, Xu X, Shen Y, et al
    Anlotinib-containing regimen for advanced small-cell lung cancer: A protocol of meta-analysis.
    PLoS One. 2021;16:e0247494.
    PubMed     Abstract available
    
    
    
64. BURNETT H, Emich H, Carroll C, Stapleton N, et al
    Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review.
    PLoS One. 2021;16:e0247620.
    PubMed     Abstract available
    
    
    
65. SIGEL K, Kong CY, Rehmani S, Bates S, et al
    Optimal treatment strategies for stage I non-small cell lung cancer in veterans with pulmonary and cardiac comorbidities.
    PLoS One. 2021;16:e0248067.
    PubMed     Abstract available
    
    
    
66. WANG S, Yang X, Wang W, Zhang Y, et al
    Interpretation of the absorbed constituents and pharmacological effect of Spica Schizonepetae extract on non-small cell lung cancer.
    PLoS One. 2021;16:e0248700.
    PubMed     Abstract available
    
    
    
67. BERNHARDSON BM, Tishelman C, Rasmussen BH, Hajdarevic S, et al
    Sensations, symptoms, and then what? Early bodily experiences prior to diagnosis of lung cancer.
    PLoS One. 2021;16:e0249114.
    PubMed     Abstract available
    
    
    
68. HUH DA, Kang MS, Lee J, Choi JY, et al
    Occupational and environmental asbestos exposure and the risk of lung cancer in Korea: A case-control study in South Chungcheong Province of Korea.
    PLoS One. 2021;16:e0249790.
    PubMed     Abstract available
    
    
    
69. NGUYEN RH, Vater LB, Timsina LR, Durm GA, et al
    Impact of smoke-free ordinance strength on smoking prevalence and lung cancer incidence.
    PLoS One. 2021;16:e0250285.
    PubMed     Abstract available
    
    
    
70. DUMONT-LEBLOND N, Veillette M, Racine C, Joubert P, et al
    Non-small cell lung cancer microbiota characterization: Prevalence of enteric and potentially pathogenic bacteria in cancer tissues.
    PLoS One. 2021;16:e0249832.
    PubMed     Abstract available
    
    
    
71. GOLDBERG E, Ievari-Shariati S, Kidane B, Kim J, et al
    Comparative metabolomics studies of blood collected in streck and heparin tubes from lung cancer patients.
    PLoS One. 2021;16:e0249648.
    PubMed     Abstract available
    
    
    
72. NINOMIYA K, Arimura H, Chan WY, Tanaka K, et al
    Robust radiogenomics approach to the identification of EGFR mutations among patients with NSCLC from three different countries using topologically invariant Betti numbers.
    PLoS One. 2021;16:e0244354.
    PubMed     Abstract available
    
    
    
73. PENG H, Sun H, Guo Y
    3D multi-scale deep convolutional neural networks for pulmonary nodule detection.
    PLoS One. 2021;16:e0244406.
    PubMed     Abstract available
    
    
    
74. CAHUANA PINTO RSM, Castro Panzenhagen A, Silva Oliveira LF, Fonseca Moreira JC, et al
    Incidence of lung cancer and mortality among civil construction industry workers: A protocol for a systematic review and meta-analysis.
    PLoS One. 2021;16:e0250377.
    PubMed     Abstract available
    
    
    
75. AYE PS, McKeage MJ, Tin Tin S, Khwaounjoo P, et al
    Population-based incidence rates and increased risk of EGFR mutated non-small cell lung cancer in Maori and Pacifica in New Zealand.
    PLoS One. 2021;16:e0251357.
    PubMed     Abstract available
    
    
    
76. HO LJ, Yang HY, Chung CH, Chang WC, et al
    Increased risk of secondary lung cancer in patients with tuberculosis: A nationwide, population-based cohort study.
    PLoS One. 2021;16:e0250531.
    PubMed     Abstract available
    
    
    
77. SAYANI A, Vahabi M, O'Brien MA, Liu G, et al
    Advancing health equity in cancer care: The lived experiences of poverty and access to lung cancer screening.
    PLoS One. 2021;16:e0251264.
    PubMed     Abstract available
    
    
    
78. ALWITHENANI A, Bethune D, Castonguay M, Drucker A, et al
    Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR.
    PLoS One. 2021;16:e0251080.
    PubMed     Abstract available
    
    
    
79. DANG X, Zhao W, Li C, Yang H, et al
    Impact of COL6A4P2 gene polymorphisms on the risk of lung cancer: A case-control study.
    PLoS One. 2021;16:e0252082.
    PubMed     Abstract available
    
    
    
80. ALLEN KL, Cann J, Zhao W, Peterson N, et al
    Correction: Upregulation of annexin A1 protein expression in the intratumoral vasculature of human non-small-cell lung carcinoma and rodent tumor models.
    PLoS One. 2021;16:e0252060.
    PubMed     Abstract available
    
    
    
81. GOFFIN JR, Corriveau S, Tang GH, Pond GR, et al
    Management and outcomes of patients with chronic obstructive lung disease and lung cancer in a public healthcare system.
    PLoS One. 2021;16:e0251886.
    PubMed     Abstract available
    
    
    
82. HEILBRONER SP, Xanthopoulos EP, Buono D, Carrier D, et al
    Efficacy and cost of high-frequency IGRT in elderly stage III non-small-cell lung cancer patients.
    PLoS One. 2021;16:e0252053.
    PubMed     Abstract available
    
    
    
83. BARATA F, Fidalgo P, Figueiredo S, Tonin FS, et al
    Limitations and perceived delays for diagnosis and staging of lung cancer in Portugal: A nationwide survey analysis.
    PLoS One. 2021;16:e0252529.
    PubMed     Abstract available
    
    
    
84. STEFANI D, Hegedues B, Collaud S, Zaatar M, et al
    Torque Teno Virus load in lung cancer patients correlates with age but not with tumor stage.
    PLoS One. 2021;16:e0252304.
    PubMed     Abstract available
    
    
    
85. FRANCO F, Carcereny E, Guirado M, Ortega AL, et al
    Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry.
    PLoS One. 2021;16:e0251761.
    PubMed     Abstract available
    
    
    
86. ROUNIS K, Makrakis D, Papadaki C, Monastirioti A, et al
    Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study.
    PLoS One. 2021;16:e0252537.
    PubMed     Abstract available
    
    
    
87. NG WW, Lin CC, Cheng CY, Jiang JS, et al
    Real-world outcomes of first- and second-generation tyrosine kinase inhibitors first-line in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: A retrospective observational cohort study.
    PLoS One. 2021;16:e0253335.
    PubMed     Abstract available
    
    
    
88. IKAWA T, Tabuchi T, Konishi K, Morimoto M, et al
    Prolonged overall treatment time negatively affects the outcomes of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: A propensity score-weighted, single-center analysis.
    PLoS One. 2021;16:e0253203.
    PubMed     Abstract available
    
    
    
89. TSAKANOVA G, Stepanyan A, Arakelova E, Ayvazyan V, et al
    The radioenhancement potential of Schiff base derived copper (II) compounds against lung carcinoma in vitro.
    PLoS One. 2021;16:e0253553.
    PubMed     Abstract available
    
    
    
90. WRIGHT GM, Gimbrone NT, Sarcar B, Percy TR, et al
    CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines.
    PLoS One. 2021;16:e0252927.
    PubMed     Abstract available
    
    
    
91. CHUNG HS, Bae S, Kim I, Ahn HY, et al
    Unexpected exposure to Mycobacterium tuberculosis during bronchoscopy using radial probe endobronchial ultrasound.
    PLoS One. 2021;16:e0246371.
    PubMed     Abstract available
    
    
    
92. CHEN DT, Chan W, Thompson ZJ, Thapa R, et al
    Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer.
    PLoS One. 2021;16:e0252041.
    PubMed     Abstract available
    
    
    
93. BOROWICZ S, Principe DR, Dorman MJ, McHenry AJ, et al
    HAI-1 is an independent predictor of lung cancer mortality and is required for M1 macrophage polarization.
    PLoS One. 2021;16:e0252197.
    PubMed     Abstract available
    
    
    
94. FUCHS J, Fruh M, Papachristofilou A, Bubendorf L, et al
    Resection of isolated brain metastases in non-small cell lung cancer (NSCLC) patients - evaluation of outcome and prognostic factors: A retrospective multicenter study.
    PLoS One. 2021;16:e0253601.
    PubMed     Abstract available
    
    
    
95. XIAO K, Liu S, Xiao Y, Wang Y, et al
    Bioinformatics prediction of differential miRNAs in non-small cell lung cancer.
    PLoS One. 2021;16:e0254854.
    PubMed     Abstract available
    
    
    
96. PEDERSEN S, Kristensen AF, Falkmer U, Christiansen G, et al
    Increased activity of procoagulant factors in patients with small cell lung cancer.
    PLoS One. 2021;16:e0253613.
    PubMed     Abstract available
    
    
    
97. ARIK A, Dodd E, Cairns A, Streftaris G, et al
    Socioeconomic disparities in cancer incidence and mortality in England and the impact of age-at-diagnosis on cancer mortality.
    PLoS One. 2021;16:e0253854.
    PubMed     Abstract available
    
    
    
98. 
    Correction: Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer.
    PLoS One. 2021;16:e0255429.
    PubMed     Abstract available
    
    
    
99. STIEB DM, Berjawi R, Emode M, Zheng C, et al
    Systematic review and meta-analysis of cohort studies of long term outdoor nitrogen dioxide exposure and mortality.
    PLoS One. 2021;16:e0246451.
    PubMed     Abstract available
    
    
    
100. LIU X, Jia Y, Shi C, Kong D, et al
     CYP4B1 is a prognostic biomarker and potential therapeutic target in lung adenocarcinoma.
     PLoS One. 2021;16:e0247020.
     PubMed     Abstract available
     
     
     
101. NONPANYA N, Sanookpan K, Joyjamras K, Wichadakul D, et al
     Norcycloartocarpin targets Akt and suppresses Akt-dependent survival and epithelial-mesenchymal transition in lung cancer cells.
     PLoS One. 2021;16:e0254929.
     PubMed     Abstract available
     
     
     
102. HUANG L, Bommireddy R, Munoz LE, Guin RN, et al
     Expression of tdTomato and luciferase in a murine lung cancer alters the growth and immune microenvironment of the tumor.
     PLoS One. 2021;16:e0254125.
     PubMed     Abstract available
     
     
     
103. PHAM DAT, Le SD, Doan TM, Luu PT, et al
     Standardization of DNA amount for bisulfite conversion for analyzing the methylation status of LINE-1 in lung cancer.
     PLoS One. 2021;16:e0256254.
     PubMed     Abstract available
     
     
     
104. SUN Z, Nyberg R, Wu Y, Bernard B, et al
     Developing an enhanced 7-color multiplex IHC protocol to dissect immune infiltration in human cancers.
     PLoS One. 2021;16:e0247238.
     PubMed     Abstract available
     
     
     
105. NAFIE E, Lolarga J, Lam B, Guo J, et al
     Harmine inhibits breast cancer cell migration and invasion by inducing the degradation of Twist1.
     PLoS One. 2021;16:e0247652.
     PubMed     Abstract available
     
     
     
106. KINOSHITA F, Tagawa T, Yamashita T, Takenaka T, et al
     Prognostic value of postoperative decrease in serum albumin on surgically resected early-stage non-small cell lung carcinoma: A multicenter retrospective study.
     PLoS One. 2021;16:e0256894.
     PubMed     Abstract available
     
     
     
107. ALOMAISH H, Ung Y, Wang S, Tyrrell PN, et al
     Survival analysis in lung cancer patients with interstitial lung disease.
     PLoS One. 2021;16:e0255375.
     PubMed     Abstract available
     
     
     
108. PRAKASH MD, Stojanovska L, Feehan J, Nurgali K, et al
     Anti-cancer effects of polyphenol-rich sugarcane extract.
     PLoS One. 2021;16:e0247492.
     PubMed     Abstract available
     
     
     
109. ANSAR A, Lewis V, McDonald CF, Liu C, et al
     Duration of intervals in the care seeking pathway for lung cancer in Bangladesh: A journey from symptoms triggering consultation to receipt of treatment.
     PLoS One. 2021;16:e0257301.
     PubMed     Abstract available
     
     
     
110. BARMPOUTIS P, Di Capite M, Kayhanian H, Waddingham W, et al
     Tertiary lymphoid structures (TLS) identification and density assessment on H&E-stained digital slides of lung cancer.
     PLoS One. 2021;16:e0256907.
     PubMed     Abstract available
     
     
     
111. AN G, Zhang Y, Chen N, Fu J, et al
     Opioid-free anesthesia compared to opioid anesthesia for lung cancer patients undergoing video-assisted thoracoscopic surgery: A randomized controlled study.
     PLoS One. 2021;16:e0257279.
     PubMed     Abstract available
     
     
     
112. KAWAGUCHI Y, Hanaoka J, Ohshio Y, Okamoto K, et al
     Sarcopenia increases the risk of post-operative recurrence in patients with non-small cell lung cancer.
     PLoS One. 2021;16:e0257594.
     PubMed     Abstract available
     
     
     
113. WINN CB, Hwang SK, Morin J, Bluette CT, et al
     Automated monitoring of respiratory rate as a novel humane endpoint: A refinement in mouse metastatic lung cancer models.
     PLoS One. 2021;16:e0257694.
     PubMed     Abstract available
     
     
     
114. NODA-NARITA S, Kawachi A, Okuyama A, Sadachi R, et al
     First-line treatment for lung cancer among Japanese older patients: A real-world analysis of hospital-based cancer registry data.
     PLoS One. 2021;16:e0257489.
     PubMed     Abstract available
     
     
     
115. CHMIELEWSKA I, Dudzinska M, Szczyrek M, Swirska J, et al
     Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab?
     PLoS One. 2021;16:e0257484.
     PubMed     Abstract available
     
     
     
116. MOK PL, Anandasayanam ANK, Oscar David HM, Tong J, et al
     Lung development, repair and cancer: A study on the role of MMP20 gene in adenocarcinoma.
     PLoS One. 2021;16:e0250552.
     PubMed     Abstract available
     
     
     
117. KREUS M, Lehtonen S, Skarp S, Kaarteenaho R, et al
     Extracellular matrix proteins produced by stromal cells in idiopathic pulmonary fibrosis and lung adenocarcinoma.
     PLoS One. 2021;16:e0250109.
     PubMed     Abstract available
     
     
     
118. JUNG J, Lee YJ, Kim CH, Ahn S, et al
     Landscape of epigenetically regulated lncRNAs and DNA methylation in smokers with lung adenocarcinoma.
     PLoS One. 2021;16:e0247928.
     PubMed     Abstract available
     
     
     
119. SHIMADA Y, Matsubayashi J, Saito A, Ohira T, et al
     Small RNA sequencing to differentiate lung squamous cell carcinomas from metastatic lung tumors from head and neck cancers.
     PLoS One. 2021;16:e0248206.
     PubMed     Abstract available
     
     
     
120. DING J, Tu Z, Chen H, Liu Z, et al
     Identifying modifiable risk factors of lung cancer: Indications from Mendelian randomization.
     PLoS One. 2021;16:e0258498.
     PubMed     Abstract available
     
     
     
121. VANECKOVA P, Wade S, Weber M, Murray JM, et al
     Birth-cohort estimates of smoking initiation and prevalence in 20th century Australia: Synthesis of data from 33 surveys and 385,810 participants.
     PLoS One. 2021;16:e0250824.
     PubMed     Abstract available
     
     
     
122. BLASI MA, Maceroni M, Caputo CG, Sammarco MG, et al
     Clinical and ultrasonographic features of choroidal metastases based on primary cancer site: Long-term experience in a single center.
     PLoS One. 2021;16:e0249210.
     PubMed     Abstract available
     
     
     
123. KATSURADA N, Tachihara M, Jimbo N, Yamamoto M, et al
     Yield of tumor samples with a large guide-sheath in endobronchial ultrasound transbronchial biopsy for non-small cell lung cancer: A prospective study.
     PLoS One. 2021;16:e0259236.
     PubMed     Abstract available
     
     
     
124. XIAO K, Wang Y, Zhou L, Wang J, et al
     Construction of ceRNA network to identify the lncRNA and mRNA related to non-small cell lung cancer.
     PLoS One. 2021;16:e0259091.
     PubMed     Abstract available
     
     
     
125. TAKAMORI S, Ohba T, Shimokawa M, Matsubara T, et al
     Prospective observational study of nutritional/immunologic indices as predictive biomarkers for the response to anti-PD-1 drugs in non-small cell lung cancer (ICI-PREDICT study).
     PLoS One. 2021;16:e0258616.
     PubMed     Abstract available
     
     
     
126. ULLGREN H, Fransson P, Olofsson A, Segersvard R, et al
     Health care utilization at end of life among patients with lung or pancreatic cancer. Comparison between two Swedish cohorts.
     PLoS One. 2021;16:e0254673.
     PubMed     Abstract available
     
     
     
127. MARFIL-SANCHEZ A, Seelbinder B, Ni Y, Varga J, et al
     Gut microbiome functionality might be associated with exercise tolerance and recurrence of resected early-stage lung cancer patients.
     PLoS One. 2021;16:e0259898.
     PubMed     Abstract available
     
     
     
128. LIU Q, Tan C, Yi L, Wan X, et al
     Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.
     PLoS One. 2021;16:e0258605.
     PubMed     Abstract available
     
     
     
129. WANG H, Yang R, Jin J, Wang Z, et al
     Impact of concomitant idiopathic pulmonary fibrosis on prognosis in lung cancer patients: A meta-analysis.
     PLoS One. 2021;16:e0259784.
     PubMed     Abstract available
     
     
     
130. LEISER D, Samanta S, Eley J, Strauss J, et al
     Role of caveolin-1 as a biomarker for radiation resistance and tumor aggression in lung cancer.
     PLoS One. 2021;16:e0258951.
     PubMed     Abstract available
     
     
     
131. CHEN YL, Chen WL, Cheng YC, Lin MC, et al
     Development of a novel ALK rearrangement screening test for non-small cell lung cancers.
     PLoS One. 2021;16:e0257152.
     PubMed     Abstract available
     
     
     
132. AIBA H, Kimura H, Yamada S, Okamoto H, et al
     Different patterns of pneumothorax in patients with soft tissue tumors treated with pazopanib: A case series analysis.
     PLoS One. 2021;16:e0254866.
     PubMed     Abstract available
     
     
     
133. KENNEY J, Ndoye A, Lamar JM, DiPersio CM, et al
     Comparative use of CRISPR and RNAi to modulate integrin alpha3beta1 in triple negative breast cancer cells reveals that some pro-invasive/pro-metastatic alpha3beta1 functions are independent of global regulation of the transcriptome.
     PLoS One. 2021;16:e0254714.
     PubMed     Abstract available
     
     
     
134. JENSEN SG, Epistolio S, Madsen CL, Kyneb MH, et al
     A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies.
     PLoS One. 2021;16:e0253687.
     PubMed     Abstract available
     
     
     
135. LI A, Deng Y, Tan Y, Chen M, et al
     A novel miRNA-disease association prediction model using dual random walk with restart and space projection federated method.
     PLoS One. 2021;16:e0252971.
     PubMed     Abstract available
     
     
     
136. MONTGOMERY MK, David J, Zhang H, Ram S, et al
     Mouse lung automated segmentation tool for quantifying lung tumors after micro-computed tomography.
     PLoS One. 2021;16:e0252950.
     PubMed     Abstract available
     
     
     
137. BUSHEY RT, Gottlin EB, Campa MJ, Patz EF Jr, et al
     Complement factor H protects tumor cell-derived exosomes from complement-dependent lysis and phagocytosis.
     PLoS One. 2021;16:e0252577.
     PubMed     Abstract available
     
     
     
138. LEE J, Bartholmai B, Peikert T, Chun J, et al
     Evaluation of Computer-Aided Nodule Assessment and Risk Yield (CANARY) in Korean patients for prediction of invasiveness of ground-glass opacity nodule.
     PLoS One. 2021;16:e0253204.
     PubMed     Abstract available
     
     
     
139. KHAN SU, Ullah F, Mehmood S, Fahad S, et al
     Antimicrobial, antioxidant and cytotoxic properties of Chenopodium glaucum L.
     PLoS One. 2021;16:e0255502.
     PubMed     Abstract available
     
     
     
140. HUNTER-SCHLICHTING D, Kelsey KT, Demmer R, Patel M, et al
     Cytomegalovirus infection in malignant pleural mesothelioma.
     PLoS One. 2021;16:e0254136.
     PubMed     Abstract available
     
     
     
141. RICE SJ, Belani CP
     Diversity and heterogeneity of immune states in non-small cell lung cancer and small cell lung cancer.
     PLoS One. 2021;16:e0260988.
     PubMed     Abstract available
     
     
     
142. YANG CZ, Hu LH, Huang ZY, Deng L, et al
     Comprehensive analysis of an immune infiltrate-related competitive endogenous RNA network reveals potential prognostic biomarkers for non-small cell lung cancer.
     PLoS One. 2021;16:e0260720.
     PubMed     Abstract available
     
     
     
143. BRASSARD J, Gill ME, Bernatchez E, Desjardins V, et al
     Countering the advert effects of lung cancer on the anticancer potential of dendritic cell populations reinstates sensitivity to anti-PD-1 therapy.
     PLoS One. 2021;16:e0260636.
     PubMed     Abstract available
     
     
     
144. CHOI W, Lee H
     Identifying disease-gene associations using a convolutional neural network-based model by embedding a biological knowledge graph with entity descriptions.
     PLoS One. 2021;16:e0258626.
     PubMed     Abstract available
     
     
     
145. ISLAM MR, Hasan ATMK, Khatun N, Ridi IN, et al
     Demographic differentials of lung cancer survival in Bangladeshi patients.
     PLoS One. 2021;16:e0261238.
     PubMed     Abstract available
     
     
     
146. DIAZ-ALVAREZ J, Roiz P, Gorospe L, Ayala A, et al
     Implementation of a lung cancer screening initiative in HIV-infected subjects.
     PLoS One. 2021;16:e0260069.
     PubMed     Abstract available
     
     
     
147. SEN'KOVA AV, Savin IA, Brenner EV, Zenkova MA, et al
     Core genes involved in the regulation of acute lung injury and their association with COVID-19 and tumor progression: A bioinformatics and experimental study.
     PLoS One. 2021;16:e0260450.
     PubMed     Abstract available
     
     
     
148. KARAMPINIS I, Rathmann N, Kostrzewa M, Diehl SJ, et al
     Computer tomography guided thoracoscopic resection of small pulmonary nodules in the hybrid theatre.
     PLoS One. 2021;16:e0258896.
     PubMed     Abstract available
     
     
     
149. TORAL KJ, Wuenschel MA, Black EP
     Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors.
     PLoS One. 2021;16:e0256416.
     PubMed     Abstract available
     
     
     
150. BREDNO J, Lipson J, Venn O, Aravanis AM, et al
     Clinical correlates of circulating cell-free DNA tumor fraction.
     PLoS One. 2021;16:e0256436.
     PubMed     Abstract available
     
     
     
151. ABLE H, Wolf-Ringwall A, Rendahl A, Ober CP, et al
     Computed tomography radiomic features hold prognostic utility for canine lung tumors: An analytical study.
     PLoS One. 2021;16:e0256139.
     PubMed     Abstract available
     
     
     
152. AIBA T, Hattori C, Sugisaka J, Shimizu H, et al
     Gene expression signatures as candidate biomarkers of response to PD-1 blockade in non-small cell lung cancers.
     PLoS One. 2021;16:e0260500.
     PubMed     Abstract available
     
     
     
153. STAVEM K, Johannessen A, Nielsen R, Gulsvik A, et al
     Respiratory symptoms and respiratory deaths: A multi-cohort study with 45 years observation time.
     PLoS One. 2021;16:e0260416.
     PubMed     Abstract available
     
     
     
154. DING M, Pan SY, Huang J, Yuan C, et al
     Optical coherence tomography for identification of malignant pulmonary nodules based on random forest machine learning algorithm.
     PLoS One. 2021;16:e0260600.
     PubMed     Abstract available
     
     
     
155. SUN B, Zhao H
     The bioinformatics analysis of RIOX2 gene in lung adenocarcinoma and squamous cell carcinoma.
     PLoS One. 2021;16:e0259447.
     PubMed     Abstract available
     
     
     January 2020
156. LU Y, Jiang J, Ren C
     The clinicopathological and prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in small cell lung cancer: A meta-analysis.
     PLoS One. 2020;15:e0230979.
     PubMed     Abstract available
     
     
     
157. CHANG PH, Lin CR, Lee YH, Liu YL, et al
     Exercise experiences in patients with metastatic lung cancer: A qualitative approach.
     PLoS One. 2020;15:e0230188.
     PubMed     Abstract available
     
     
     
158. ZHANG Y, Pavlov A, Malik S, Chen H, et al
     Efficacy of a small molecule inhibitor of the transcriptional cofactor PC4 in prevention and treatment of non-small cell lung cancer.
     PLoS One. 2020;15:e0230670.
     PubMed     Abstract available
     
     
     
159. VON ITZSTEIN MS, Gupta A, Kernstine KH, Mara KC, et al
     Increased reporting but decreased mortality associated with adverse events in patients undergoing lung cancer surgery: Competing forces in an era of heightened focus on care quality?
     PLoS One. 2020;15:e0231258.
     PubMed     Abstract available
     
     
     
160. YOON HJ, Kang J, Park H, Sohn I, et al
     Deciphering the tumor microenvironment through radiomics in non-small cell lung cancer: Correlation with immune profiles.
     PLoS One. 2020;15:e0231227.
     PubMed     Abstract available
     
     
     
161. COOK GW, Benton MG, Akerley W, Mayhew GF, et al
     Structural variation and its potential impact on genome instability: Novel discoveries in the EGFR landscape by long-read sequencing.
     PLoS One. 2020;15:e0226340.
     PubMed     Abstract available
     
     
     
162. STEINER B, Ferrucci LM, Mirabello L, Lan Q, et al
     Association between coffee drinking and telomere length in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
     PLoS One. 2020;15:e0226972.
     PubMed     Abstract available
     
     
     
163. HYUN DG, Choi CM, Lee DH, Kim SW, et al
     Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis.
     PLoS One. 2020;15:e0231546.
     PubMed     Abstract available
     
     
     
164. SANCHEZ-CARPINTERO ABAD M, Sanchez-Salcedo P, de-Torres JP, Alcaide AB, et al
     Prevalence and burden of bronchiectasis in a lung cancer screening program.
     PLoS One. 2020;15:e0231204.
     PubMed     Abstract available
     
     
     
165. NIU QL, Sun H, Liu C, Li J, et al
     Croton tiglium essential oil compounds have anti-proliferative and pro-apoptotic effects in A549 lung cancer cell lines.
     PLoS One. 2020;15:e0231437.
     PubMed     Abstract available
     
     
     
166. 
     Retraction: Identification and Characterization of Cells with Cancer Stem Cell Properties in Human Primary Lung Cancer Cell Lines.
     PLoS One. 2020;15:e0232726.
     PubMed    
     
     
     
167. NYGARD L, Ahlborn LB, Persson GF, Chandrananda D, et al
     Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients - initial observations.
     PLoS One. 2020;15:e0231884.
     PubMed     Abstract available
     
     
     
168. RUIYING C, Zeyun L, Yongliang Y, Zijia Z, et al
     A comprehensive analysis of metabolomics and transcriptomics in non-small cell lung cancer.
     PLoS One. 2020;15:e0232272.
     PubMed     Abstract available
     
     
     
169. BLOCKER SJ, Holbrook MD, Mowery YM, Sullivan DC, et al
     The impact of respiratory gating on improving volume measurement of murine lung tumors in micro-CT imaging.
     PLoS One. 2020;15:e0225019.
     PubMed     Abstract available
     
     
     
170. LIM JH, Choi JY, Im Y, Yoo H, et al
     Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma.
     PLoS One. 2020;15:e0229299.
     PubMed     Abstract available
     
     
     
171. JUSTO N, Nilsson J, Korytowsky B, Dalen J, et al
     Retrospective observational cohort study on innovation in oncology and progress in survival: How far have we gotten in the two decades of treating patients with advanced non-small cell lung cancer as a single population?
     PLoS One. 2020;15:e0232669.
     PubMed     Abstract available
     
     
     
172. LU Y, Liu X, Zhang E, Kopras EJ, et al
     Estrogen activates pyruvate kinase M2 and increases the growth of TSC2-deficient cells.
     PLoS One. 2020;15:e0228894.
     PubMed     Abstract available
     
     
     
173. BARR MP, Gray SG, Hoffmann AC, Hilger RA, et al
     Correction: Generation and Characterisation of Cisplatin-Resistant Non-Small Cell Lung Cancer Cell Lines Displaying a Stem-Like Signature.
     PLoS One. 2020;15:e0233739.
     PubMed     Abstract available
     
     
     
174. MIN KW, Kim WS, Kim DH, Son BK, et al
     High polymerase epsilon expression associated with increased CD8+T cells improves survival in patients with non-small cell lung cancer.
     PLoS One. 2020;15:e0233066.
     PubMed     Abstract available
     
     
     
175. WALLRABENSTEIN T, Del Rio J, Templeton AJ, Buess M, et al
     Much has changed in the last decade except overall survival: A Swiss single center analysis of treatment and survival in patients with stage IV non-small cell lung cancer.
     PLoS One. 2020;15:e0233768.
     PubMed     Abstract available
     
     
     
176. BANGAOIL R, Santillan A, Angeles LM, Abanilla L, et al
     ATR-FTIR spectroscopy as adjunct method to the microscopic examination of hematoxylin and eosin-stained tissues in diagnosing lung cancer.
     PLoS One. 2020;15:e0233626.
     PubMed     Abstract available
     
     
     
177. KANG S, Kim TH, Shin JM, Han K, et al
     Optimization of a chest computed tomography protocol for detecting pure ground glass opacity nodules: A feasibility study with a computer-assisted detection system and a lung cancer screening phantom.
     PLoS One. 2020;15:e0232688.
     PubMed     Abstract available
     
     
     
178. ALLEN KL, Cann J, Zhao W, Peterson N, et al
     Upregulation of annexin A1 protein expression in the intratumoral vasculature of human non-small-cell lung carcinoma and rodent tumor models.
     PLoS One. 2020;15:e0234268.
     PubMed     Abstract available
     
     
     
179. CHEN R, Lin J
     Identification of feature risk pathways of smoking-induced lung cancer based on SVM.
     PLoS One. 2020;15:e0233445.
     PubMed     Abstract available
     
     
     
180. YOON HY, Ryu JS, Sim YS, Kim D, et al
     Clinical significance of EGFR mutation types in lung adenocarcinoma: A multi-centre Korean study.
     PLoS One. 2020;15:e0228925.
     PubMed     Abstract available
     
     
     
181. LI B, Dai C, Wang L, Deng H, et al
     A novel drug repurposing approach for non-small cell lung cancer using deep learning.
     PLoS One. 2020;15:e0233112.
     PubMed     Abstract available
     
     
     
182. MU Q, Yu J, Griffin JI, Wu Y, et al
     Novel drug combination nanoparticles exhibit enhanced plasma exposure and dose-responsive effects on eliminating breast cancer lung metastasis.
     PLoS One. 2020;15:e0228557.
     PubMed     Abstract available
     
     
     
183. TERAMOTO A, Tsukamoto T, Yamada A, Kiriyama Y, et al
     Deep learning approach to classification of lung cytological images: Two-step training using actual and synthesized images by progressive growing of generative adversarial networks.
     PLoS One. 2020;15:e0229951.
     PubMed     Abstract available
     
     
     
184. KEMBOU NZALE S, Weeks WB, Ouafik L, Rouquette I, et al
     Inequity in access to personalized medicine in France: Evidences from analysis of geo variations in the access to molecular profiling among advanced non-small-cell lung cancer patients: Results from the IFCT Biomarkers France Study.
     PLoS One. 2020;15:e0234387.
     PubMed     Abstract available
     
     
     
185. CHEN R, Lin J
     Correction: Identification of feature risk pathways of smoking-induced lung cancer based on SVM.
     PLoS One. 2020;15:e0235854.
     PubMed     Abstract available
     
     
     
186. STEINHAUSER MOTTA JP, Steffen RE, Samary Lobato C, Souza Mendonca V, et al
     Endobronchial ultrasound-guided transbronchial needle aspiration versus mediastinoscopy for mediastinal staging of lung cancer: A systematic review of economic evaluation studies.
     PLoS One. 2020;15:e0235479.
     PubMed     Abstract available
     
     
     
187. SONG MJ, Kim DJ, Paik HC, Cho S, et al
     Impact of idiopathic pulmonary fibrosis on recurrence after surgical treatment for stage I-III non-small cell lung cancer.
     PLoS One. 2020;15:e0235126.
     PubMed     Abstract available
     
     
     
188. LOPEZ-GARCIA G, Jerez JM, Franco L, Veredas FJ, et al
     Transfer learning with convolutional neural networks for cancer survival prediction using gene-expression data.
     PLoS One. 2020;15:e0230536.
     PubMed     Abstract available
     
     
     
189. WITNEY TH, Fortt R, Aboagye EO
     Correction: Preclinical Assessment of Carboplatin Treatment Efficacy in Lung Cancer by 18F-ICMT-11-Positron Emission Tomography.
     PLoS One. 2020;15:e0235804.
     PubMed     Abstract available
     
     
     
190. ABE T, Nakashima C, Sato A, Harada Y, et al
     Origin of circulating free DNA in patients with lung cancer.
     PLoS One. 2020;15:e0235611.
     PubMed     Abstract available
     
     
     
191. YANG SC, Lai WW, Hsu JC, Su WC, et al
     Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: Analysis of real-world data in a tertiary hospital in Taiwan.
     PLoS One. 2020;15:e0231413.
     PubMed     Abstract available
     
     
     
192. SMEDA M, Kij A, Proniewski B, Matyjaszczyk-Gwarda K, et al
     Unexpected effects of long-term treatment with acetylsalicylic acid on late phase of pulmonary metastasis in murine model of orthotopic breast cancer.
     PLoS One. 2020;15:e0230520.
     PubMed     Abstract available
     
     
     
193. LI Y, He CL, Li WX, Zhang RX, et al
     Transcriptome analysis reveals gender-specific differences in overall metabolic response of male and female patients in lung adenocarcinoma.
     PLoS One. 2020;15:e0230796.
     PubMed     Abstract available
     
     
     
194. CHOI HD, Chang MJ
     Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: A meta-analysis.
     PLoS One. 2020;15:e0234818.
     PubMed     Abstract available
     
     
     
195. LEE CY, Fujino K, Motooka Y, Gregor A, et al
     Photoacoustic imaging to localize indeterminate pulmonary nodules: A preclinical study.
     PLoS One. 2020;15:e0231488.
     PubMed     Abstract available
     
     
     
196. WARSAVAGE T JR, Xing F, Baron AE, Feser WJ, et al
     Quantifying the incremental value of deep learning: Application to lung nodule detection.
     PLoS One. 2020;15:e0231468.
     PubMed     Abstract available
     
     
     
197. WANG C, Zhang J, Zhou S, Yu L, et al
     Tentative identification of gefitinib metabolites in non-small-cell lung cancer patient plasma using ultra-performance liquid chromatography coupled with triple quadrupole time-of-flight mass spectrometry.
     PLoS One. 2020;15:e0236523.
     PubMed     Abstract available
     
     
     
198. KIM N, Kim JS, Geol Lee C
     Predictive value of interim 18F-FDG-PET in patients with non-small cell lung cancer treated with definitive radiation therapy.
     PLoS One. 2020;15:e0236350.
     PubMed     Abstract available
     
     
     
199. GASILINA A, Premnauth G, Gurjar P, Biesiada J, et al
     IODVA1, a guanidinobenzimidazole derivative, targets Rac activity and Ras-driven cancer models.
     PLoS One. 2020;15:e0229801.
     PubMed     Abstract available
     
     
     
200. RIBEIRO TB, Buss L, Wayant C, Nobre MRC, et al
     Comparison of FDA accelerated vs regular pathway approvals for lung cancer treatments between 2006 and 2018.
     PLoS One. 2020;15:e0236345.
     PubMed     Abstract available
     
     
     
201. 
     Retraction: Histone Deacetylase Inhibitors Sensitize Lung Cancer Cells to Hyperthermia: Involvement of Ku70/SirT-1 in Thermo-Protection.
     PLoS One. 2020;15:e0237589.
     PubMed    
     
     
     
202. FORSYTHE ML, Alwithenani A, Bethune D, Castonguay M, et al
     Molecular profiling of non-small cell lung cancer.
     PLoS One. 2020;15:e0236580.
     PubMed     Abstract available
     
     
     
203. QIAN C, Liu H, Feng Y, Meng S, et al
     Clinical characteristics and risk of second primary lung cancer after cervical cancer: A population-based study.
     PLoS One. 2020;15:e0231807.
     PubMed     Abstract available
     
     
     
204. ARIK A, Dodd E, Streftaris G
     Cancer morbidity trends and regional differences in England-A Bayesian analysis.
     PLoS One. 2020;15:e0232844.
     PubMed     Abstract available
     
     
     
205. KANG JK, Heo S, Kim HP, Song SH, et al
     Liquid biopsy-based tumor profiling for metastatic colorectal cancer patients with ultra-deep targeted sequencing.
     PLoS One. 2020;15:e0232754.
     PubMed     Abstract available
     
     
     
206. LEVEQUE E, Lacourt A, Philipps V, Luce D, et al
     A new trajectory approach for investigating the association between an environmental or occupational exposure over lifetime and the risk of chronic disease: Application to smoking, asbestos, and lung cancer.
     PLoS One. 2020;15:e0236736.
     PubMed     Abstract available
     
     
     
207. MEIKLE CK, Meisler AJ, Bird CM, Jeffries JA, et al
     Platelet-T cell aggregates in lung cancer patients: Implications for thrombosis.
     PLoS One. 2020;15:e0236966.
     PubMed     Abstract available
     
     
     
208. GRATZ M, Ruhlmann V, Umutlu L, Fenchel M, et al
     Impact of respiratory motion correction on lesion visibility and quantification in thoracic PET/MR imaging.
     PLoS One. 2020;15:e0233209.
     PubMed     Abstract available
     
     
     
209. NASRI NASRABADI P, Nayeri Z, Gharib E, Salmanipour R, et al
     Establishment of a CALU, AURKA, and MCM2 gene panel for discrimination of metastasis from primary colon and lung cancers.
     PLoS One. 2020;15:e0233717.
     PubMed     Abstract available
     
     
     
210. KLINGLER A, Regensburger D, Tenkerian C, Britzen-Laurent N, et al
     Species-, organ- and cell-type-dependent expression of SPARCL1 in human and mouse tissues.
     PLoS One. 2020;15:e0233422.
     PubMed     Abstract available
     
     
     
211. LARSON KL, Huang B, Chen Q, Tucker T, et al
     EGFR testing and erlotinib use in non-small cell lung cancer patients in Kentucky.
     PLoS One. 2020;15:e0237790.
     PubMed     Abstract available
     
     
     
212. PARK KY, Kim J
     Cyclic pentapeptide cRGDfK enhances the inhibitory effect of sunitinib on TGF-beta1-induced epithelial-to-mesenchymal transition in human non-small cell lung cancer cells.
     PLoS One. 2020;15:e0232917.
     PubMed     Abstract available
     
     
     
213. LU JJ, Li P, Yang Y, Wang L, et al
     Prognostic value of LAT-1 status in solid cancer: A systematic review and meta-analysis.
     PLoS One. 2020;15:e0233629.
     PubMed     Abstract available
     
     
     
214. KIM MS, Kim SH, Yang SH, Kim MS, et al
     Restricting extracellular Ca2+ on gefitinib-resistant non-small cell lung cancer cells reverses altered epidermal growth factor-mediated Ca2+ response, which consequently enhances gefitinib sensitivity.
     PLoS One. 2020;15:e0238155.
     PubMed     Abstract available
     
     
     
215. CHEN JL, Wu JN, Lv XD, Yang QC, et al
     The value of red blood cell distribution width, neutrophil-to-lymphocyte ratio, and hemoglobin-to-red blood cell distribution width ratio in the progression of non-small cell lung cancer.
     PLoS One. 2020;15:e0237947.
     PubMed     Abstract available
     
     
     
216. REMON J, Swalduz A, Planchard D, Ortiz-Cuaran S, et al
     Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay.
     PLoS One. 2020;15:e0234302.
     PubMed     Abstract available
     
     
     
217. SANTOS-SANCHEZ V, Cordoba-Dona JA, Viciana F, Escolar-Pujolar A, et al
     Geographical variations in cancer mortality and social inequalities in southern Spain (Andalusia). 2002-2013.
     PLoS One. 2020;15:e0233397.
     PubMed     Abstract available
     
     
     
218. FU L, Wang H, Wei D, Wang B, et al
     The value of CEP55 gene as a diagnostic biomarker and independent prognostic factor in LUAD and LUSC.
     PLoS One. 2020;15:e0233283.
     PubMed     Abstract available
     
     
     
219. DING H, Xin W, Tong Y, Sun J, et al
     Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review.
     PLoS One. 2020;15:e0238536.
     PubMed     Abstract available
     
     
     
220. SUTTON AJ, Sagoo GS, Jackson L, Fisher M, et al
     Cost-effectiveness of a new autoantibody test added to Computed Tomography (CT) compared to CT surveillance alone in the diagnosis of lung cancer amongst patients with indeterminate pulmonary nodules.
     PLoS One. 2020;15:e0237492.
     PubMed     Abstract available
     
     
     
221. GOLDSBURY DE, Weber MF, Yap S, Rankin NM, et al
     Health services costs for lung cancer care in Australia: Estimates from the 45 and Up Study.
     PLoS One. 2020;15:e0238018.
     PubMed     Abstract available
     
     
     
222. LIU J, Li J, Lin G, Long Z, et al
     Risk factors of lobar lymph node metastases in non-primary tumor-bearing lobes among the patients of non-small-cell lung cancer.
     PLoS One. 2020;15:e0239281.
     PubMed     Abstract available
     
     
     
223. LEE JY, Fan CC, Chou NL, Lin HW, et al
     PHRF1 promotes migration and invasion by modulating ZEB1 expression.
     PLoS One. 2020;15:e0236876.
     PubMed     Abstract available
     
     
     
224. SCHUZ J, Bukhtiyarov I, Olsson A, Moissonnier M, et al
     Occupational cohort study of current and former workers exposed to chrysotile in mine and processing facilities in Asbest, the Russian Federation: Cohort profile of the Asbest Chrysotile Cohort study.
     PLoS One. 2020;15:e0236475.
     PubMed     Abstract available
     
     
     
225. THRONICKE A, Reinhold T, von Trott P, Grah C, et al
     Cost-effectiveness of real-world administration of chemotherapy and add-on Viscum album L. therapy compared to chemotherapy in the treatment of stage IV NSCLC patients.
     PLoS One. 2020;15:e0236426.
     PubMed     Abstract available
     
     
     
226. HONG S, Youk T, Lee SJ, Kim KM, et al
     Bone metastasis and skeletal-related events in patients with solid cancer: A Korean nationwide health insurance database study.
     PLoS One. 2020;15:e0234927.
     PubMed     Abstract available
     
     
     
227. TANG S, Yang M, Bai J
     Detection of pulmonary nodules based on a multiscale feature 3D U-Net convolutional neural network of transfer learning.
     PLoS One. 2020;15:e0235672.
     PubMed     Abstract available
     
     
     
228. STEMMER A, Shadmi R, Bregman-Amitai O, Chettrit D, et al
     Using machine learning algorithms to review computed tomography scans and assess risk for cardiovascular disease: Retrospective analysis from the National Lung Screening Trial (NLST).
     PLoS One. 2020;15:e0236021.
     PubMed     Abstract available
     
     
     
229. VIRANI NA, Kelada OJ, Kunjachan S, Detappe A, et al
     Noninvasive imaging of tumor hypoxia after nanoparticle-mediated tumor vascular disruption.
     PLoS One. 2020;15:e0236245.
     PubMed     Abstract available
     
     
     
230. HUNG HY, Tseng YH, Chao HS, Chiu CH, et al
     Multidisciplinary team discussion results in survival benefit for patients with stage III non-small-cell lung cancer.
     PLoS One. 2020;15:e0236503.
     PubMed     Abstract available
     
     
     
231. TU C, Pi Y, Xing S, Ling Y, et al
     Integrated analysis of long non-coding RNAs and mRNA profiles reveals potential sex-dependent biomarkers of bevacizumab/erlotinib response in advanced lung cancer.
     PLoS One. 2020;15:e0240633.
     PubMed     Abstract available
     
     
     
232. LIU X, Huang G, Zhang J, Zhang L, et al
     Prognostic and clinicopathological significance of long noncoding RNA MALAT-1 expression in patients with non-small cell lung cancer: A meta-analysis.
     PLoS One. 2020;15:e0240321.
     PubMed     Abstract available
     
     
     
233. SHIRE NJ, Klein AB, Golozar A, Collins JM, et al
     STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world.
     PLoS One. 2020;15:e0238358.
     PubMed     Abstract available
     
     
     
234. THOMAS S, Carroll JC, Brown MC, Chen Z, et al
     Nicotine dependence as a risk factor for upper aerodigestive tract (UADT) cancers: A mediation analysis.
     PLoS One. 2020;15:e0237723.
     PubMed     Abstract available
     
     
     
235. GUO CY, Chou YC
     A novel machine learning strategy for model selections - Stepwise Support Vector Machine (StepSVM).
     PLoS One. 2020;15:e0238384.
     PubMed     Abstract available
     
     
     
236. SAKAI A, Tagami M, Kakehashi A, Katsuyama-Yoshikawa A, et al
     Expression, intracellular localization, and mutation of EGFR in conjunctival squamous cell carcinoma and the association with prognosis and treatment.
     PLoS One. 2020;15:e0238120.
     PubMed     Abstract available
     
     
     
237. CHANIAD P, Trakunran K, Geater SL, Keeratichananont W, et al
     Serum miRNAs associated with tumor-promoting cytokines in non-small cell lung cancer.
     PLoS One. 2020;15:e0241593.
     PubMed     Abstract available
     
     
     
238. GU JJ, Hoj J, Rouse C, Pendergast AM, et al
     Mesenchymal stem cells promote metastasis through activation of an ABL-MMP9 signaling axis in lung cancer cells.
     PLoS One. 2020;15:e0241423.
     PubMed     Abstract available
     
     
     
239. TONG J, Krieger JR, Taylor P, Bagshaw R, et al
     Cancer proteome and metabolite changes linked to SHMT2.
     PLoS One. 2020;15:e0237981.
     PubMed     Abstract available
     
     
     
240. TAKADA K, Takamori S, Matsubara T, Haratake N, et al
     Clinical significance of preoperative inflammatory markers in non-small cell lung cancer patients: A multicenter retrospective study.
     PLoS One. 2020;15:e0241580.
     PubMed     Abstract available
     
     
     
241. BOGNAR Z, Cseh AM, Fekete K, Antus C, et al
     Amiodarone's major metabolite, desethylamiodarone inhibits proliferation of B16-F10 melanoma cells and limits lung metastasis formation in an in vivo experimental model.
     PLoS One. 2020;15:e0239088.
     PubMed     Abstract available
     
     
     
242. BANDA M, McKim KL, Myers MB, Inoue M, et al
     Outgrowth of erlotinib-resistant subpopulations recapitulated in patient-derived lung tumor spheroids and organoids.
     PLoS One. 2020;15:e0238862.
     PubMed     Abstract available
     
     
     
243. CHEN B, Li H, Liu C, Xiang X, et al
     Prognostic value of the common tumour-infiltrating lymphocyte subtypes for patients with non-small cell lung cancer: A meta-analysis.
     PLoS One. 2020;15:e0242173.
     PubMed     Abstract available
     
     
     
244. KOMATSU T, Chen-Yoshikawa TF, Ikeda M, Takahashi K, et al
     Impact of diabetes mellitus on postoperative outcomes in individuals with non-small-cell lung cancer: A retrospective cohort study.
     PLoS One. 2020;15:e0241930.
     PubMed     Abstract available
     
     
     
245. CHANG TC, Matossian MD, Elliott S, Burks HE, et al
     Evaluation of deacetylase inhibition in metaplastic breast carcinoma using multiple derivations of preclinical models of a new patient-derived tumor.
     PLoS One. 2020;15:e0226464.
     PubMed     Abstract available
     
     
     
246. NOORTMAN WA, Vriens D, Slump CH, Bussink J, et al
     Adding the temporal domain to PET radiomic features.
     PLoS One. 2020;15:e0239438.
     PubMed     Abstract available
     
     
     
247. TETZLAFF F, Epping J, Golpon H, Tetzlaff J, et al
     Compression, expansion, or maybe both? Growing inequalities in lung cancer in Germany.
     PLoS One. 2020;15:e0242433.
     PubMed     Abstract available
     
     
     
248. YOGO N, Hase T, Kasama T, Nishiyama K, et al
     Development of an immuno-wall device for the rapid and sensitive detection of EGFR mutations in tumor tissues resected from lung cancer patients.
     PLoS One. 2020;15:e0241422.
     PubMed     Abstract available
     
     
     
249. CHEN X, Wang L, Su X, Luo SY, et al
     Identification of potential target genes and crucial pathways in small cell lung cancer based on bioinformatic strategy and human samples.
     PLoS One. 2020;15:e0242194.
     PubMed     Abstract available
     
     
     
250. WANG Q, Xu L, Wang G, Chen L, et al
     Prognostic and clinicopathological significance of NRF2 expression in non-small cell lung cancer: A meta-analysis.
     PLoS One. 2020;15:e0241241.
     PubMed     Abstract available
     
     
     
251. MORENO-BARBOSA F, de Celis-Alonso B, Moreno-Barbosa E, Hernandez-Lopez JM, et al
     Monte Carlo simulation of the effect of magnetic fields on brachytherapy dose distributions in lung tissue material.
     PLoS One. 2020;15:e0238704.
     PubMed     Abstract available
     
     
     
252. STRATMANN JA, Lacko R, Ballo O, Shaid S, et al
     Colonization with multi-drug-resistant organisms negatively impacts survival in patients with non-small cell lung cancer.
     PLoS One. 2020;15:e0242544.
     PubMed     Abstract available
     
     
     
253. KODA E, Yamashiro T, Onoe R, Handa H, et al
     CT texture analysis of mediastinal lymphadenopathy: Combining with US-based elastographic parameter and discrimination between sarcoidosis and lymph node metastasis from small cell lung cancer.
     PLoS One. 2020;15:e0243181.
     PubMed     Abstract available
     
     
     
254. KIM T, Cha YJ, Park JH, Kim A, et al
     Reactive oxygen species modulator 1 expression predicts lymph node metastasis and survival in early-stage non-small cell lung cancer.
     PLoS One. 2020;15:e0239670.
     PubMed     Abstract available
     
     
     
255. YU G, Shen Y, Xu X, Zhong F, et al
     Anlotinib for refractory advanced non-small-cell lung cancer: A systematic review and meta-analysis.
     PLoS One. 2020;15:e0242982.
     PubMed     Abstract available
     
     
     
256. MCLAUGHLIN MF, Alam M, Smith L, Ryckman J, et al
     Stereotactic body radiation therapy mitigates radiation induced lymphopenia in early stage non-small cell lung cancer.
     PLoS One. 2020;15:e0241505.
     PubMed     Abstract available
     
     
     
257. JIN J, Robeson H, Fagan P, Orloff MS, et al
     Association of PARP1-specific polymorphisms and haplotypes with non-small cell lung cancer subtypes.
     PLoS One. 2020;15:e0243509.
     PubMed     Abstract available
     
     
     
258. TENDLER S, Kanter L, Lewensohn R, Ortiz-Villalon C, et al
     The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression in SCLC patients receiving platinum-based chemotherapy.
     PLoS One. 2020;15:e0240973.
     PubMed     Abstract available
     
     
     
259. TANG L, Chen N, He W, Zhou J, et al
     The clinicopathological features and prognosis of primary pulmonary lymphoepithelioma-like carcinoma: A systematic review and meta-analysis.
     PLoS One. 2020;15:e0240729.
     PubMed     Abstract available
     
     
     
260. ERDAL BS, Demirer M, Little KJ, Amadi CC, et al
     Are quantitative features of lung nodules reproducible at different CT acquisition and reconstruction parameters?
     PLoS One. 2020;15:e0240184.
     PubMed     Abstract available
     
     
     
261. NOTO FK, Sangodkar J, Adedeji BT, Moody S, et al
     The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies.
     PLoS One. 2020;15:e0240169.
     PubMed     Abstract available
     
     
     
262. LEE HS, Jung JI, Kim KH, Park SJ, et al
     Toxicodendron vernicifluum Stokes extract inhibits solid tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c mice.
     PLoS One. 2020;15:e0241805.
     PubMed     Abstract available
     
     
     
263. CHEN HJ, Tu CY, Huang KY, Chien CR, et al
     Early serum tumor marker levels after fourteen days of tyrosine kinase inhibitor targeted therapy predicts outcomes in patients with advanced lung adenocarcinoma.
     PLoS One. 2020;15:e0240736.
     PubMed     Abstract available
     
     
     
264. YU H, Gu D, Qian P
     Prognostic value of ESR2 expression on adjuvant chemotherapy in completely resected NSCLC.
     PLoS One. 2020;15:e0243891.
     PubMed     Abstract available
     
     
     
265. UCHIDA Y, Tsugawa T, Tanaka-Mizuno S, Noma K, et al
     Prediction of radiation pneumonitis using dose-volume histogram parameters with high attenuation in two types of cancer: A retrospective study.
     PLoS One. 2020;15:e0244143.
     PubMed     Abstract available
     
     
     
266. CHEN YH, Wang TF, Chu SC, Lin CB, et al
     Incorporating radiomic feature of pretreatment 18F-FDG PET improves survival stratification in patients with EGFR-mutated lung adenocarcinoma.
     PLoS One. 2020;15:e0244502.
     PubMed     Abstract available
     
     
     
267. BONERT M, Schneider M, Solyanik O, Hellbach K, et al
     Diagnostic accuracy of magnetic resonance imaging for the detection of pulmonary nodules simulated in a dedicated porcine chest phantom.
     PLoS One. 2020;15:e0244382.
     PubMed     Abstract available
     
     
     
268. TOYODA Y, Tabuchi T, Hama H, Morishima T, et al
     Trends in clinical stage distribution and screening detection of cancer in Osaka, Japan: Stomach, colorectum, lung, breast and cervix.
     PLoS One. 2020;15:e0244644.
     PubMed     Abstract available
     
     
     
269. GOMI T, Hara H, Watanabe Y, Mizukami S, et al
     Improved digital chest tomosynthesis image quality by use of a projection-based dual-energy virtual monochromatic convolutional neural network with super resolution.
     PLoS One. 2020;15:e0244745.
     PubMed     Abstract available
     
     
     
270. WANG L, Wang W, Zeng S, Zheng H, et al
     Construction and validation of a 6-gene nomogram discriminating lung metastasis risk of breast cancer patients.
     PLoS One. 2020;15:e0244693.
     PubMed     Abstract available
     
     
     January 2019
271. BERENT TE, Dorschner JM, Meyer T, Craig TA, et al
     Impaired cardiac performance, protein synthesis, and mitochondrial function in tumor-bearing mice.
     PLoS One. 2019;14:e0226440.
     PubMed     Abstract available
     
     
     
272. CHUN YJ, Choi JW, Hong MH, Jung D, et al
     Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing.
     PLoS One. 2019;14:e0224379.
     PubMed     Abstract available
     
     
     
273. TANAKA T, Akiyoshi H, Nishida H, Mie K, et al
     Contrast-enhanced computed tomography findings of canine primary renal tumors including renal cell carcinoma, lymphoma, and hemangiosarcoma.
     PLoS One. 2019;14:e0225211.
     PubMed     Abstract available
     
     
     
274. KIM A, Lee SJ, Ahn J, Park WY, et al
     The prognostic significance of tumor-infiltrating lymphocytes assessment with hematoxylin and eosin sections in resected primary lung adenocarcinoma.
     PLoS One. 2019;14:e0224430.
     PubMed     Abstract available
     
     
     
275. MOON DH, Park CH, Kang DY, Lee HS, et al
     Significance of the lobe-specific emphysema index to predict prolonged air leak after anatomical segmentectomy.
     PLoS One. 2019;14:e0224519.
     PubMed     Abstract available
     
     
     
276. CHOI W, Kim SH, Kang SH, Park JJ, et al
     Differential impact of smoking on cardiac or non-cardiac death according to age.
     PLoS One. 2019;14:e0224486.
     PubMed     Abstract available
     
     
     
277. VINCENTEN JPL, van Essen HF, Lissenberg-Witte BI, Bulkmans NWJ, et al
     Clonality analysis of pulmonary tumors by genome-wide copy number profiling.
     PLoS One. 2019;14:e0223827.
     PubMed     Abstract available
     
     
     
278. GU K, Lee HY, Lee K, Choi JY, et al
     Integrated evaluation of clinical, pathological and radiological prognostic factors in squamous cell carcinoma of the lung.
     PLoS One. 2019;14:e0223298.
     PubMed     Abstract available
     
     
     
279. HE Y, Liu H, Wang S, Chen Y, et al
     Prognostic nomogram predicts overall survival in pulmonary large cell neuroendocrine carcinoma.
     PLoS One. 2019;14:e0223275.
     PubMed     Abstract available
     
     
     
280. TAMIRAT MZ, Koivu M, Elenius K, Johnson MS, et al
     Structural characterization of EGFR exon 19 deletion mutation using molecular dynamics simulation.
     PLoS One. 2019;14:e0222814.
     PubMed     Abstract available
     
     
     
281. GER RB, Meier JG, Pahlka RB, Gay S, et al
     Effects of alterations in positron emission tomography imaging parameters on radiomics features.
     PLoS One. 2019;14:e0221877.
     PubMed     Abstract available
     
     
     
282. RAI SN, Srivastava S, Pan J, Wu X, et al
     Multi-group diagnostic classification of high-dimensional data using differential scanning calorimetry plasma thermograms.
     PLoS One. 2019;14:e0220765.
     PubMed     Abstract available
     
     
     
283. MARSHALL EA, Stewart GL, Sage AP, Lam WL, et al
     Beyond sequence homology: Cellular biology limits the potential of XIST to act as a miRNA sponge.
     PLoS One. 2019;14:e0221371.
     PubMed     Abstract available
     
     
     
284. CHEN HC, Tan EC, Liao CH, Lin ZZ, et al
     Development and validation of nomograms for predicting survival probability of patients with advanced adenocarcinoma in different EGFR mutation status.
     PLoS One. 2019;14:e0220730.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: